Licochalcone A is a potent inhibitor of TEL-Jak2-mediated transformation through the specific inhibition of Stat3 activation

Biochemical Pharmacology

Volumn 76, Issue 12, 2008, Pages 1681-1693

  Funakoshi Tago, Megumi ^a   Tago, Kenji ^b   Nishizawa, Chiho ^a   Takahashi, Kyoko ^a   Mashino, Tadahiko ^a   Iwata, Susumu ^c   Inoue, Hideo ^c   Sonoda, Yoshiko ^a   Kasahara, Tadashi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Graduate School of Biological Sciences   (Japan)

^c Minophagen Pharmaceutical Co Ltd   (Japan)

Author keywords

Glycyrrhiza inflate; Licochalcone; Stat3; TEL Jak2

Indexed keywords

INTERLEUKIN 3; JANUS KINASE 2; LICOCHALCONE A; STAT3 PROTEIN; TRANSCRIPTION FACTOR ETV6;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHALCONES; INTERLEUKIN-3; LEUKEMIA; MICE; ONCOGENE PROTEINS, FUSION; PLANT EXTRACTS; STAT3 TRANSCRIPTION FACTOR;

EID: 56549085955     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.012     Document Type: Article

References (41)

1. Ihle J.N. Cytokine receptor signalling. Nature 377 (1995) 591-594
2. O'Shea J.J., Notarangelo L.D., Johnston J.A., and Candotti F. Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol 17 (1997) 431-447
3. Feng J., Witthuhn B.A., Matsuda T., Kohlhuber F., Kerr I.M., and Ihle J.N. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17 (1997) 2497-2501
4. Chatti K., Farrar W.L., and Duhe R.J. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43 (2004) 4272-4283
5. Yamaoka K., Saharinen P., Pesu M., Holt III V.E., Silvennoinen O., and O'Shea J.J. The Janus kinases (Jaks). Genome Biol 5 (2004) 253
6. Lindauer K., Loerting T., Liedl K.R., and Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 14 (2001) 27-37
7. Saharinen P., and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277 (2002) 47954-47963
8. Saharinen P., Vihinen M., and Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14 (2003) 1448-1459
9. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
10. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
11. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90 (1997) 2535-2540
12. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278 (1997) 1309-1312
13. Ho J.M., Beattie B.K., Squire J.A., Frank D.A., and Barber D.L. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93 (1999) 4354-4364
14. Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95 (2000) 3891-3899
15. Nguyen M.H., Ho J.M., Beattie B.K., and Barber D.L. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem 276 (2001) 32704-32713
16. Santos S.C., Lacronique V., Bouchaert I., Monni R., Bernard O., Gisselbrecht S., et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway. Oncogene 20 (2001) 2080-2090
17. Ho J.M., Nguyen M.H., Dierov J.K., Badger K.M., Beattie B.K., Tartaro P., et al. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood 100 (2002) 1438-1448
18. Malinge S., Monni R., Bernard O., and Penard-Lacronique V. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 25 (2006) 3589-3597
19. Hatano T., Kagawa H., Yasuhara T., and Okuda T. Two new flavonoids and other constituents in licorice root: their relative astringency and radical scavenging effects. Chem Pharm Bull (Tokyo) 36 (1988) 2090-2097
20. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120 (2000) 849-862
21. Inoue H., Iwata S., Ma R.D., Yu L.J., Ueyama H., Takayasu J., et al. Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflata root on inflammatory ear edema and tumour promotion in mice. Planta Med 57 (1991) 221-224
22. Chen M., Christensen S.B., Blom J., Lemmich E., Nadelmann L., Fich K., et al. Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother 37 (1993) 2550-2556
23. Funakoshi-Tago M., Pelletier S., Moritake H., Parganas E., and Ihle J.N. Jak2 FERM domain interaction with the Erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 28 (2008) 1792-1801
24. Ichikawa D., Funakoshi-Tago M., Aizu-Yokota E., Sonoda Y., Inoue J., and Kasahara T. TNF-receptor associated factor 6-deficient fibroblast is sensitive to the TNF-alpha-induced cell death: involvement of reactive oxygen species. Biochem Biophys Res Commun 351 (2006) 93-98
25. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R., et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6 (2006) 693-704
26. Wegenka U.M., Buschmann J., Lutticken C., Heinrich P.C., and Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13 (1993) 276-288
27. Bonni A., Sun Y., Nadal-Vicens M., Bhatt A., Frank D.A., Rozovsky I., et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278 (1997) 477-483
28. Gouilleux-Gruart V., Gouilleux F., Desaint C., Claisse J.F., Capiod J.C., Delobel J., et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87 (1996) 1692-1697
29. Garcia R., Yu C.L., Hundall A., Catlett R., Nelson K.L., Smithgall T., et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8 (1997) 1267-1276
30. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
31. Dechow T.N., Pedranzini L., Leitch A., Leslie K., Gerald W.L., Linkov I., et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101 (2004) 10602-10607
32. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2000) 2000-2008
33. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
34. Galm O., Yoshikawa H., Esteller M., Osieka R., and Herman J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101 (2003) 2784-2788
35. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100 (2003) 14133-14138
36. Weber A., Hengge U.R., Bardenheuer W., Tischoff I., Sommerer F., Markwarth A., et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24 (2005) 6699-6708
37. Hatirnaz O., Ure U., Ar C., Akyerli C., Soysal T., Ferhanoǧlu B., et al. The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am J Hematol 82 (2007) 729-730
38. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98 (2001) 7319-7324
39. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23 (2004) 8017-8023
40. Schlessinger K., and Levy D.E. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 65 (2005) 5828-5834
41. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., and Frank D.A. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66 (2006) 3162-3168